Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
SPd2kDEa5uQgGzCD
